Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo

Retraction in: /10.3892/or.2021.8235

  • Authors:
    • Songyang Liu
    • Wei Zhang
    • Kai Liu
    • Yingchao Wang
    • Bai Ji
    • Yahui Liu
  • View Affiliations

  • Published online on: September 19, 2014     https://doi.org/10.3892/or.2014.3503
  • Pages: 2501-2510
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A disintegrin and metalloproteinase 10 (ADAM10) has been demonstrated to correlate with hepatocellular carcinoma (HCC) grade and clinical outcome and its potential as a target for HCC therapy has been established. Gene associated with retinoid-interferon-induced mortality 19 (GRIM-19), a signal transducer and activator of transcription 3 (Stat3)-inhibitory protein, was identified as a potential tumor suppressor associated with growth inhibition and cell apoptosis. In the present study, we investigated whether a combined treatment with ADAM10-specific siRNA and GRIM19 gene could have an enhanced anticancer effectiveness on HCC in vitro and in vivo. We developed a dual expression plasmid that co-expressed ADAM10-specific siRNA and GRIM19, to evaluate its effects on HCC growth. Our results showed that simultaneous expression of ADAM10-specific siRNA and GRIM19 (pSi-ADAM10-GRIM19) in HepG2 cancer cells significantly inhibited the proliferation, migration and invasion, and induced cell apoptosis in vitro, and it also suppressed tumor growth in a nude mouse model when compared to the controls, either ADAM10-specific siRNA or GRIM-19 alone. In summary, our data demonstrated that a combined strategy of co-expressed ADAM10-specific siRNA and GRIM19 synergistically and more effectively suppressed HCC tumor growth, and has therapeutic potential for the treatment of HCC.
View Figures
View References

Related Articles

Journal Cover

December-2014
Volume 32 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu S, Zhang W, Liu K, Wang Y, Ji B and Liu Y: Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo Retraction in /10.3892/or.2021.8235. Oncol Rep 32: 2501-2510, 2014
APA
Liu, S., Zhang, W., Liu, K., Wang, Y., Ji, B., & Liu, Y. (2014). Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo Retraction in /10.3892/or.2021.8235. Oncology Reports, 32, 2501-2510. https://doi.org/10.3892/or.2014.3503
MLA
Liu, S., Zhang, W., Liu, K., Wang, Y., Ji, B., Liu, Y."Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo Retraction in /10.3892/or.2021.8235". Oncology Reports 32.6 (2014): 2501-2510.
Chicago
Liu, S., Zhang, W., Liu, K., Wang, Y., Ji, B., Liu, Y."Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo Retraction in /10.3892/or.2021.8235". Oncology Reports 32, no. 6 (2014): 2501-2510. https://doi.org/10.3892/or.2014.3503